Related Experiment Video

Updated: Aug 15, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Selective Inhibition of CK2: Emerging Strategies and Future Directions

Aryaman R Sokhal1, Sona Krajcovicova1,2, Jessica Iegre1

  • 1Yusuf Hamied Department of Chemistry, University of Cambridge, CambridgeCB2 1EW, United Kingdom.

Journal of Medicinal Chemistry
|August 13, 2026
PubMed

Insights

Developing selective inhibitors for Casein Kinase 2 (CK2) is crucial for treating cancer and neurodegenerative diseases. Novel strategies targeting the CK2α/β interface and the αD pocket have yielded promising dual-site inhibitors, with one now in clinical trials.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Drug Discovery

Background:

  • Casein Kinase 2 (CK2) is a serine/threonine kinase involved in various cellular processes and diseases.
  • Its constitutive activity and complex structure pose challenges for selective inhibition.
  • Targeting CK2 is a promising therapeutic strategy for cancer and neurodegeneration.

Purpose of the Study:

  • To review and discuss complementary strategies for achieving selective CK2 inhibition.
  • To highlight the development of small molecules and peptides targeting the CK2α/β interface.
  • To explore the exploitation of the cryptic αD pocket for dual-site inhibitor design.

Main Methods:

  • Small molecule inhibitors targeting the CK2α/β interface (e.g., CAM187, CAM7117, P8C9).
  • Conformationally constrained peptides disrupting the CK2α/β interface.
  • Dual-site inhibitor design exploiting the cryptic αD pocket (e.g., CAM4066, CAM4712, AB668, KDX1381, Biv5).

Main Results:

  • CK2α/β-interface inhibitors demonstrated modulation of holoenzyme assembly and substrate phosphorylation.
  • Validation of the αD pocket as a ligandable site enabled novel inhibitor development.
  • Development of highly selective, subnanomolar dual-site inhibitors, including APL-5125.

Conclusions:

  • Multiple strategies have been successfully employed for selective CK2 inhibition.
  • The αD pocket offers a valuable target for advanced inhibitor design.
  • APL-5125 represents a significant advancement, entering Phase 1/2 clinical trials for potential therapeutic applications.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...